$RCKT
ROCKET PHARMACEUTICALS, INC.

2018 Q1 Form 10-K Financial Statement

#000156459018004621 Filed on March 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.660M $1.740M $4.860M
YoY Change 1367.8% -131.24% 207.59%
% of Gross Profit
Research & Development $5.740M $4.920M $14.19M
YoY Change 150.66% -55.63%
% of Gross Profit
Depreciation & Amortization $80.00K $60.00K $200.0K
YoY Change 31.15% -250.0% 18.34%
% of Gross Profit
Operating Expenses $14.41M $6.660M $14.19M
YoY Change 402.09% -130.18% -55.63%
Operating Profit -$26.74M
YoY Change -36.16%
Interest Expense -$1.140M $0.00 $3.579M
YoY Change -230.14% 152.4%
% of Operating Profit
Other Income/Expense, Net $200.0K $0.00 $190.0K
YoY Change -100.0%
Pretax Income -$15.34M -$6.660M -$19.58M
YoY Change 434.49% -129.85% 158.65%
Income Tax
% Of Pretax Income
Net Earnings -$15.34M -$6.660M -$29.50M
YoY Change 43.8% -129.85% -31.17%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$424.5K -$979.4K -$2.879M
COMMON SHARES
Basic Shares Outstanding 39.40M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $182.7M $18.10M $18.10M
YoY Change 59.29% -85.69% -85.69%
Cash & Equivalents $171.1M $78.72M $18.10M
Short-Term Investments $11.60M $0.00 $0.00
Other Short-Term Assets $2.100M $800.0K $800.0K
YoY Change 10.53% -57.89% -57.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $184.8M $101.0M $19.00M
YoY Change 58.45% -21.27% -85.19%
LONG-TERM ASSETS
Property, Plant & Equipment $1.100M $563.0K $1.000M
YoY Change -1.96% -50.18% -9.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $168.0K $200.0K
YoY Change 138.1% 0.0% 0.0%
Total Long-Term Assets $32.40M $731.0K $1.100M
YoY Change 2411.63% -43.68% -15.38%
TOTAL ASSETS
Total Short-Term Assets $184.8M $101.0M $19.00M
Total Long-Term Assets $32.40M $731.0K $1.100M
Total Assets $217.2M $101.8M $20.10M
YoY Change 84.19% -21.5% -84.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.0K $451.0K $0.00
YoY Change -94.74% -71.67% -100.0%
Accrued Expenses $7.100M $2.373M $4.500M
YoY Change 146.02% -44.11% -15.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.300M $4.070M $4.500M
YoY Change 37.74% -42.2% -35.71%
LONG-TERM LIABILITIES
Long-Term Debt $39.10M $0.00 $0.00
YoY Change -20.37% -100.0% -100.0%
Other Long-Term Liabilities $600.0K $403.0K $100.0K
YoY Change 100.0% -15.51% -80.0%
Total Long-Term Liabilities $39.70M $403.0K $100.0K
YoY Change -19.64% -15.51% -99.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.300M $4.070M $4.500M
Total Long-Term Liabilities $39.70M $403.0K $100.0K
Total Liabilities $47.00M $54.01M $4.600M
YoY Change -14.08% -4.36% -91.86%
SHAREHOLDERS EQUITY
Retained Earnings -$268.4M
YoY Change 12.35%
Common Stock $316.2M
YoY Change 1.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $170.1M $15.52M $15.50M
YoY Change
Total Liabilities & Shareholders Equity $217.2M $101.8M $20.10M
YoY Change 84.22% -21.5% -84.49%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017
OPERATING ACTIVITIES
Net Income -$15.34M -$6.660M -$29.50M
YoY Change 43.8% -129.85% -31.17%
Depreciation, Depletion And Amortization $80.00K $60.00K $200.0K
YoY Change 31.15% -250.0% 18.34%
Cash From Operating Activities -$11.60M -$5.990M -$15.96M
YoY Change 211.83% -129.04% 190.18%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$30.00K -$760.0K
YoY Change -92.31% 123.53%
Acquisitions
YoY Change
Other Investing Activities $86.09M $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $86.08M -$30.00K -$760.0K
YoY Change -66315.38% -100.13% 123.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 78.52M 0.000 25.41M
YoY Change 264.36% -100.0% 126950.0%
NET CHANGE
Cash From Operating Activities -11.60M -5.990M -15.96M
Cash From Investing Activities 86.08M -30.00K -760.0K
Cash From Financing Activities 78.52M 0.000 25.41M
Net Change In Cash 153.0M -6.020M 8.690M
YoY Change 764.41% -31.44% -249.31%
FREE CASH FLOW
Cash From Operating Activities -$11.60M -$5.990M -$15.96M
Capital Expenditures -$10.00K -$30.00K -$760.0K
Free Cash Flow -$11.59M -$5.960M -$15.20M
YoY Change 222.84% -128.89% 194.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Entity Registrant Name
EntityRegistrantName
ROCKET PHARMACEUTICALS, INC.
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001281895
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-41879000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-26737000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12544000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9894000
CY2017 dei Trading Symbol
TradingSymbol
RCKT
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29798000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
96675000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1876000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
128349000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1130000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
270000
CY2016Q4 us-gaap Assets
Assets
129647000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1592000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4246000
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39402023
CY2017Q2 dei Entity Public Float
EntityPublicFloat
45400000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78720000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
21294000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1033000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
101047000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
563000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
168000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
168000
CY2017Q4 us-gaap Assets
Assets
101778000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
451000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2373000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1246000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1204000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
477000
CY2016Q4 us-gaap Liabilities
Liabilities
56479000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
67000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
312032000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238877000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-54000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
73168000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129647000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6746579
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6746579
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31985000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
443000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-29497000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-42854000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.36
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.41
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6765451
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6683794
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-43000
CY2017 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-29459000
CY2016 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-42897000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
108813000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2909000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
191000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
155000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3997000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4036000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
35000
CY2017 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
16000
CY2017 rckt Noncash Interest Expense
NoncashInterestExpense
581000
CY2016 rckt Noncash Interest Expense
NoncashInterestExpense
222000
CY2017 rckt Noncash Rent
NoncashRent
59000
CY2016 rckt Noncash Rent
NoncashRent
60000
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
437000
CY2017 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
217000
CY2016 us-gaap Interest Expense
InterestExpense
1418000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4070000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7042000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
403000
CY2017Q4 us-gaap Liabilities
Liabilities
54014000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
68000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
316086000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268374000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
47764000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101778000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6805686
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6805686
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14193000
CY2017 us-gaap Interest Expense
InterestExpense
3579000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
819000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
75015000
CY2016 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
225000
CY2017 us-gaap Depreciation
Depreciation
200000
CY2016 us-gaap Depreciation
Depreciation
169000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
4036000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2909000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-960000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
948000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1141000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-41000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1846000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3112000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26112000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37266000
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
27204000
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
122277000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
102289000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
56705000
CY2017 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
70000
CY2016 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
487000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-66059000
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3997000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
53081000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
48922000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-50244000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80042000
CY2017 us-gaap Interest Paid
InterestPaid
2957000
CY2017 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
38000
CY2016 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-43000
CY2017Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
100014000
CY2017 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2016 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates<font style="font-weight:normal;">&#8212;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from these estimates. Significant items subject to such estimates and assumptions include the valuation of stock options used for the calculation of stock-based compensation and </font><font style="font-weight:normal;">the calculation of accruals related to research and clinical development.</font></p></div>
CY2016 rckt Lease Amendment Commencement Date
LeaseAmendmentCommencementDate
2016-07-01
CY2015Q1 rckt Proceeds From Issuance Of Common Stock And Convertible Senior Notes
ProceedsFromIssuanceOfCommonStockAndConvertibleSeniorNotes
55398000
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
73965000
CY2016Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
48738000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
38000
CY2016 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-43000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
21310000
CY2017 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
16000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
21294000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
96729000
CY2016 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
1000
CY2016 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
55000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
96675000
CY2017Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2016Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2017 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Shorter of useful life or remaining life of lease
CY2017 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
greater than 50 percent
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2016 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29497000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42854000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2430288
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2421413
CY2017 rckt Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRatePercentage
0.00
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
898000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1561000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
335000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
431000
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
217000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
793000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1627000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
528000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
311000
CY2017Q4 rckt Government Payables Current
GovernmentPayablesCurrent
506000
CY2016Q4 rckt Government Payables Current
GovernmentPayablesCurrent
478000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
544000
CY2017Q4 rckt Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
151000
CY2016Q4 rckt Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1148000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
125000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
138000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0434
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0476
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0176
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0338
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0604
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0174
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.7956
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.4550
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4040
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37252000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43765000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
16115000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
22775000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1722000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1963000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55089000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
68503000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-13414000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17312000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
127132000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
83428000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
535000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
488000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
333000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
6000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
51000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
149000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
4000
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote per share
CY2017 rckt Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
3
CY2017 rckt Number Of Common Stock Surrendered By Employees For Payment
NumberOfCommonStockSurrenderedByEmployeesForPayment
3270
CY2017 rckt Net Issuance Of Shares Excluding Common Stock Surrendered By Employees For Payment
NetIssuanceOfSharesExcludingCommonStockSurrenderedByEmployeesForPayment
53136
CY2017Q4 rckt Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested But Remain Unsettled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButRemainUnsettledInPeriod
29375
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4036000
CY2016 rckt Lease Term Period
LeaseTermPeriod
P90M
CY2017 rckt Merger Agreement Consummation Date
MergerAgreementConsummationDate
2018-01-04
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2909000
CY2015 rckt Lease Commencement Date
LeaseCommencementDate
2015-09
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
445000
CY2016 rckt Lease Extend Term
LeaseExtendTerm
P5Y
CY2016 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The lease term is 90 months and Inotek has the right to extend the term for one period of five years.
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
337000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
275000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
411000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
421000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
430000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
439000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
445000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
74000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2220000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
154000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
168000
CY2017 rckt Defined Contribution Savings Plan Expiration Date
DefinedContributionSavingsPlanExpirationDate
2018-01-03

Files In Submission

Name View Source Status
0001564590-18-004621-index-headers.html Edgar Link pending
0001564590-18-004621-index.html Edgar Link pending
0001564590-18-004621.txt Edgar Link pending
0001564590-18-004621-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030616433011938124.jpg Edgar Link pending
g2018030616434935638124.jpg Edgar Link pending
g2018030616434946938125.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rckt-10k_20171231.htm Edgar Link pending
rckt-20171231.xml Edgar Link completed
rckt-20171231.xsd Edgar Link pending
rckt-20171231_cal.xml Edgar Link unprocessable
rckt-20171231_def.xml Edgar Link unprocessable
rckt-20171231_lab.xml Edgar Link unprocessable
rckt-20171231_pre.xml Edgar Link unprocessable
rckt-ex1010_755.htm Edgar Link pending
rckt-ex1012_198.htm Edgar Link pending
rckt-ex102_201.htm Edgar Link pending
rckt-ex103_200.htm Edgar Link pending
rckt-ex109_199.htm Edgar Link pending
rckt-ex211_9.htm Edgar Link pending
rckt-ex231_10.htm Edgar Link pending
rckt-ex311_7.htm Edgar Link pending
rckt-ex312_6.htm Edgar Link pending
rckt-ex321_8.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending